Acoustic ejection mass spectrometry empowers ultra-fast protein biomarker quantification

Bart Puyvelde, Christie L. Hunter, Maxim Zhgamadze, Sudha Savant, Y. Oliver Wang, Esthelle Hoedt, Koen Raedschelders, Matt Pope, Carissa A. Huynh, V. Krishnan Ramanujan, Warren Tourtellotte, Morteza Razavi, N. Leigh Anderson, Geert Martens, Dieter Deforce, Qin Fu, Maarten Dhaenens () and Jennifer E. Eyk ()
Additional contact information
Bart Puyvelde: Ghent University
Christie L. Hunter: SCIEX
Maxim Zhgamadze: Cedars-Sinai Medical Center
Sudha Savant: Beckman Coulter Life Sciences
Y. Oliver Wang: Cedars-Sinai Medical Center
Esthelle Hoedt: Cedars-Sinai Medical Center
Koen Raedschelders: Cedars-Sinai Medical Center
Matt Pope: SISCAPA Assay Technologies Inc.
Carissa A. Huynh: Cedars-Sinai Medical Center
V. Krishnan Ramanujan: Cedars-Sinai Medical Center
Warren Tourtellotte: Cedars-Sinai Medical Center
Morteza Razavi: SISCAPA Assay Technologies Inc.
N. Leigh Anderson: SISCAPA Assay Technologies Inc.
Geert Martens: AZ Delta General Hospital
Dieter Deforce: Ghent University
Qin Fu: Cedars-Sinai Medical Center
Maarten Dhaenens: Ghent University
Jennifer E. Eyk: Cedars-Sinai Medical Center

Nature Communications, 2024, vol. 15, issue 1, 1-11

Abstract: Abstract The global scientific response to COVID 19 highlighted the urgent need for increased throughput and capacity in bioanalytical laboratories, especially for the precise quantification of proteins that pertain to health and disease. Acoustic ejection mass spectrometry (AEMS) represents a much-needed paradigm shift for ultra-fast biomarker screening. Here, a quantitative AEMS assays is presented, employing peptide immunocapture to enrich (i) 10 acute phase response (APR) protein markers from plasma, and (ii) SARS-CoV-2 NCAP peptides from nasopharyngeal swabs. The APR proteins were quantified in 267 plasma samples, in triplicate in 4.8 h, with %CV from 4.2% to 10.5%. SARS-CoV-2 peptides were quantified in triplicate from 145 viral swabs in 10 min. This assay represents a 15-fold speed improvement over LC-MS, with instrument stability demonstrated across 10,000 peptide measurements. The combination of speed from AEMS and selectivity from peptide immunocapture enables ultra-high throughput, reproducible quantitative biomarker screening in very large cohorts.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-48563-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48563-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-48563-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().